Home News Covid-19

Singapore to build vaccine manufacturing capacity: PM Lee

Bloomberg
Bloomberg6/5/2020 11:38 AM GMT+08  • 1 min read
Singapore to build vaccine manufacturing capacity: PM Lee
Singapore is building up its vaccine manufacturing capacity in order to offer fill and finish contract manufacturing services to vaccine developers, Singapore Prime Minister Lee Hsien Loong said in published remarks delivered at a summit.
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

(June 5): Singapore is building up its vaccine manufacturing capacity in order to offer fill and finish contract manufacturing services to vaccine developers, Singapore Prime Minister Lee Hsien Loong said in published remarks delivered at a summit.

  • The effort is aimed at helping companies ramp up production faster and assure them high standards of safety and quality in the manufacturing process, Lee said.
  • The country is investing heavily in research and development on diagnostics, vaccines and therapeutics, he said.
    • Singapore researchers have developed a range of serological and nucleic acid-based diagnostic tests, which have been deployed to over 20 countries.
    • Researchers are also developing therapeutic monoclonal antibodies as well as a vaccine and have started clinical trials of various therapeutics, he added.
  • Earlier, Singapore Focuses on Jobs in New $33 Billion Virus Relief (3)

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.